Target oncology partners MI Bioresearch specializes in preclinical oncology pharmacology with in vivo imaging, focal radiation, and a broad tumor model library. This positions them as a potential CRO partner for companies seeking end-to-end preclinical oncology services, creating opportunities to offer integrated preclinical packages or collaboration on asset-specific studies.

Broad model diversity Access to over 350 cell lines across multiple histotypes and various tumor models (SC, disseminated, orthotopic, orthotopic glioblastoma, metastatic) enables tailored study design for diverse cancer programs. Sales opportunities exist to match client assets with optimized in vitro and in vivo models, accelerating trial readiness.

Imaging and radiation capabilities In house small animal imaging (CT, PET, bioluminescence, fluorescence) plus targeted radiation via SARRP provide advanced imaging and radiotherapy support. These capabilities can be cross-sold to clients needing repeated imaging endpoints or experimental radiotherapy components within preclinical studies.

Data-driven design Extensive historic in vivo data and FSPx clinical data management experience from acquisitions position MI Bioresearch as a trusted data partner. Potential upsell includes data management, study design optimization, and regulatory-ready datasets to de-risk candidate progression.

Growth and collaborations As a Covance preclinical Oncology solutions arm with strategic acquisitions and expanding capabilities, MI Bioresearch presents a compelling alliance for large biotech and pharma firms seeking integrated CRO ecosystems. There are opportunities to bundle services with other Covance or Covance-affiliated entities for comprehensive drug development programs.